TELA Bio appears in FDA device records as the applicant behind a single 510(k) clearance in the collection reviewed here, and its own published materials describe a broader soft-tissue reconstruction business. The two strands are worth separating: the regulatory record establishes who filed, for which device, and under what classification, while the company's website and investor releases describe how it characterizes its products and strategy. The profile below stays with what those documents state and leaves unstated details, including manufacturing scale and commercial uptake, as unknown. [1][3][4][8]

The Liora clearance and its filing scope

FDA records show K260474 for the Liora Monofilament Scaffold, received February 12, 2026, and decided September 28, 2026, with decision code SESE and the description Substantially Equivalent. The record lists product code FTL, regulation number 878.3300, Class II, advisory committee General and Plastic Surgery, and a Traditional clearance type with a summary statement. The applicant address on the filing is 1 Great Valley Pkwy., Suite 24, Malvern, Pennsylvania. [1]

The FDA clearance letter dated September 28, 2026 is addressed to John Urtz, Director - Regulatory and Quality, at the same Malvern address, and identifies the trade name Liora Monofilament Scaffold under 21 CFR 878.3300, Surgical Mesh, Class II, product code FTL. The letter records the submission as dated and received August 26, 2026. The letter also includes a comparison table listing mean major pore size values for the subject device and a predicate, with an Equivalent conclusion. [2]

How the company describes Liora

TELA Bio’s release dated October 5, 2026 announces the 510(k) clearance and describes Liora as a fully resorbable surgical mesh device for soft tissue reinforcement. The release is issued from Malvern, Pennsylvania, and describes TELA Bio as a commercial-stage medical technology company focused on soft-tissue reconstruction. It does not state launch timing, pricing or clinical results. [3]

A second posting of the same announcement carries the same October 5, 2026 date and the same description of the clearance and of Liora as a fully resorbable surgical mesh for soft tissue reinforcement. Both postings list Louisa Smith as investor contact. Neither document provides performance data, and no independent clinical evidence appears in the numbered sources. [9]

Company identity and published product framing

TELA Bio's investor relations page identifies the company as TELA Bio Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on designing, developing, and marketing tissue reinforcement products. The same page lists recent 8-K filings dated October 8, October 6, October 5 and September 29, 2026. A Form 8-K with an earliest event date of October 5, 2026 identifies TELA Bio, Inc. as a Delaware registrant with commission file number 001-39130. [8][6]

On its corporate site, TELA Bio states that it provides soft-tissue reconstruction solutions intended to preserve and restore the patient's own anatomy while minimizing long-term exposure to permanent synthetic materials, and it presents the OviTex Reinforced Tissue Matrix under hernia and abdominal wall reconstruction. The same site references OviTex PRS LTR. These are the company's own characterizations, published on its website, rather than findings from the FDA filing. [4]

The company's about page repeats the description of focusing on gaps in soft-tissue surgical innovation and on minimizing long-term exposure to permanent synthetic materials, and it names Antony Koblish as co-founder and chief executive officer, Jeffrey Blizard as president, Roberto Cuca as chief operating officer and chief financial officer, and Paul Talmo as chief technology officer. A separate about page lists a board of directors including Doug Evans as chairman. [7][5]

What the record does and does not establish

The collection reviewed here contains one linked 510(k) record, decided SESE, and no recall records. That count describes the filings assembled as of the snapshot date and is not a measure of total company sales, total portfolio or safety performance. The recordSample holds the single K260474 entry, and the decision counts for the full collection and for that sample are both one, so no ratio beyond that single filing should be inferred. [1]

Several details remain unknown from these documents: manufacturing sites, unit volumes, hospital customers, reimbursement status and post-market experience for Liora. The FDA record lists numerous establishment identifiers in its openFDA fields, but those fields are not a statement about where Liora is made. Claims about clinical benefit or comparative performance are absent from the numbered sources and are not made here. [1][2]